Site-specific Chemotherapy Based on Predicted Primary Site by Pathological Profile for Carcinoma of Unknown Primary Site.

[1]  R. Tothill,et al.  Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. , 2016, The Lancet. Oncology.

[2]  A. Gown,et al.  Practical Applications in Immunohistochemistry: Carcinomas of Unknown Primary Site. , 2016, Archives of pathology & laboratory medicine.

[3]  J. Hainsworth,et al.  Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care , 2014, Virchows Archiv.

[4]  J. Hainsworth,et al.  Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Hahn,et al.  Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis , 2012, British Journal of Cancer.

[6]  M. Erlander,et al.  Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Yasuhiro Fujiwara,et al.  Immunohistochemical Profile for Unknown Primary Adenocarcinoma , 2012, PloS one.

[8]  Masahiro Fukuoka,et al.  Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Trikalinos,et al.  Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced Colorectal Cancer , 2011, Annals of Internal Medicine.

[10]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[11]  N. Pavlidis,et al.  Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Hainsworth,et al.  Paclitaxel/Carboplatin/Etoposide Versus Gemcitabine/Irinotecan in the First-Line Treatment of Patients With Carcinoma of Unknown Primary Site: A Randomized, Phase III Sarah Cannon Oncology Research Consortium Trial , 2010, Cancer journal.

[13]  F. Monzon,et al.  Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Oien,et al.  Pathologic evaluation of unknown primary cancer. , 2009, Seminars in oncology.

[15]  M. Ando,et al.  Irinotecan plus carboplatin for patients with carcinoma of unknown primary site , 2008, British Journal of Cancer.

[16]  Arno Floore,et al.  Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Komorowski,et al.  Markers of Adenocarcinoma Characteristic of the Site of Origin: Development of a Diagnostic Algorithm , 2005, Clinical Cancer Research.

[18]  N. Kimura,et al.  Podoplanin as a marker for mesothelioma , 2005, Pathology international.

[19]  Howard,et al.  Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. , 2004, The oncologist.

[20]  A. Piga,et al.  Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site , 2004, British Journal of Cancer.

[21]  J. Hainsworth,et al.  Diagnostic and therapeutic management of cancer of an unknown primary. , 2003, European journal of cancer.

[22]  N. Ordóñez.  The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma , 2003, The American journal of surgical pathology.

[23]  C. la Vecchia,et al.  Epidemiology of unknown primary tumours. , 2002, European journal of cancer.

[24]  A. Renshaw,et al.  Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. , 2000, The American journal of surgical pathology.

[25]  M. O'brien,et al.  Metastatic adenocarcinoma of an unknown primary site. A comparison of the relative contributions of morphology, minimal essential clinical data and CEA immunostaining status. , 1993, American journal of clinical pathology.

[26]  M. Zabel,et al.  Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours. , 2007, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[27]  J. Coebergh,et al.  Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. , 2002, European journal of cancer.